The Orphan Drugs Leader. With 2012 exceeding $500 million, BioMarin has vaulted itself into an elite group of the top-tier biotech companies. Naglazyme ($257 million, +14% Y/Y) and Kuvan ($143 million, +23%) each had solid years and royalties from Aldurazyme ($80 million, +6%) continue to deliver strong cash flow. With a truly impressive pipeline filled[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.